Our mission is to support our patients with mental or neurological disorders from the initial diagnostic to the end of the intervention, offering them state of the art technology to evaluate and treat ...
Stockhead on MSN
Entropy’s psilocybin therapy shows rapid and sustained reduction of binge eating in 100pc of patients
Entropy Neurodynamics has received positive Phase 2a results for its psilocybin-based therapy in patients with Binge Eating ...
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat ...
Trailing total returns as of 12/23/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) Return TYPTF S&P/ASX 200 [XJO] (^AXJO) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback